Lifevantage Corporation

Research Lifevantage Corporation (LFVN) on Bullrun: valuation model: 4.8% undervalued, market cap USD 78.22M, P/E 13.9, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Lifevantage Corporation as 4.8% undervalued; latest market cap is USD 78.22M; P/E is 13.9; dividend yield is 3.1%.

About Lifevantage Corporation

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health;

Frequently asked questions

Is Lifevantage Corporation overvalued or undervalued?

Bullrun's valuation model currently marks Lifevantage Corporation as 4.8% undervalued.

What is Lifevantage Corporation's market cap?

Lifevantage Corporation's market capitalization is USD 78.22M.

What is Lifevantage Corporation's P/E ratio?

Lifevantage Corporation's price-to-earnings (P/E) ratio is 13.9.

Does Lifevantage Corporation pay a dividend?

Lifevantage Corporation has a dividend yield of 3.1%.

What does Lifevantage Corporation do?

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement;